AMERICAS

摘要

Pharma company actavis's US$8.4bn equity and equity-linked acquisition financing will dominate the attention of ECM syndicate desks this week but bankers also expect the IPO business to grind back into action after a relatively quiet few weeks. Actavis is scheduled to price its offerings, part of a broader US$30bn-plus permanent funding package on Thursday, though the long marketing period and the stock's strong reaction may enable bookrunners to accelerate pricing or increase the size of the deal (See Top News). The holiday-shortened week made for a slow few days for ECM deals. Only US$1.5bn was raised, all in the form of secondary offerings and dominated by a US$900m sponsor selldown of shares in food services company aramarr, a block trade led by Credit Suisse. Bankers expect to see IPO launches picking up over the next weeks.